# Cizzle Biotechnology revises US payments as lung cancer test rollout advances

- Link: https://www.directorstalkinterviews.com/cizzle-biotechnology-revises-us-payments-as-lung-cancer-test-rollout-advances/4121266435
- Published: 2026-10-15T07:05:00+01:00
- Author: Amilia Stone

**Cizzle Biotechnology Holdings plc** (LON:CIZ), the UK based diagnostics developer
of early cancer tests, has provided an update on progress in the USA towards early
adoption of its proprietary test for the CIZ1B biomarker, which is highly associated
with early-stage lung cancer.

**Highlights**

•         The Company and BIO have successfully achieved the Test’s validation in
a CLIA accredited laboratory in the USA and BIO is rolling out the Test to larger,
more centralised CLIA laboratories as part of a strategy to achieve national coverage.

•         As part of the exclusive licensing agreement between the Company and BIO,
the Company has received upfront and advance royalties.

•         The Company and BIO have now agreed to recognise all advance royalty payments
as upfront or milestone payments, enabling the Company to benefit from immediate
royalties based on early sales adoption.

•         The Company has agreed to realign its guaranteed future royalty payments
over the period ending December 2027 instead of December 2026, and has an option
to convert these payments into capital stock in BIO, at the Company’s election.

Following validation of the Test in a Clinical Laboratory Improvement Amendments(
CLIA) accredited laboratory, the Company’s North American licensing partner Cizzle
Bio Inc (BIO) entered into an agreement with a second CLIA-accredited laboratory,
BioBridge Global (BBG), to offer the Test to licensed healthcare providers, as announced
on 3 August 2026.

BIO is investing in PR, sales and marketing and has identified key opinion leaders,
clinicians and select targeted private pay opportunities to deliver early sales.
In addition, BIO is in discussions with further CLIA-accredited laboratories regarding
offering the Test. The Company believes that this diversification, part of BIO’s
phased strategy to build a network of high-quality laboratory partners across the
United States, reduces risk associated with a single delivery facility.

On 23 February 2026, the Company announced that it had received US$590,000 from 
BIO, comprising US$100,000 of initial exclusivity fees and US$490,000 of advance
royalties, as part of guaranteed advance payments totalling US$2.4 million due by
31 December 2026. The remaining US$1.81 million was due to be paid by that date.
BIO has not made the remaining payments and is not expected to pay the full US$1.81
million to the Company by 31 December 2026 under that schedule.

Therefore, the Company and BIO have agreed a variation to the payment schedule (
the “Variation”). Under the Variation, the remaining US$1.81 million of guaranteed
advance payments will be paid by 31 December 2027, rather than by 31 December 2026,
in accordance with a revised schedule aligned with BIO’s sales and marketing plans.
In addition, the US$490,000 of advance royalties already received and future payments
of advance royalties will be treated as non-refundable upfront or milestone payments
rather than as advances against future royalties, so that the Company will receive
royalties from initial sales of the Test. As part of the Variation, the Company 
may elect to convert the deferred payments into capital stock of BIO at the price
achieved by BIO in its next fundraising or, if no such fundraising takes place, 
at fair market value at the date of a conversion notice. The further minimum guaranteed
payments of US$3.5 million on extension of the agreement in 2031, announced on 23
February 2026, are unaffected by the Variation.

**Background to and reasons for the Variation**

On 16 June 2026, the Company announced that the Test had successfully completed 
laboratory validation and had been approved for use under CLIA at OmniHealth Diagnostics(“
OmniHealth”).  The Test was then made available to selected clinicians on 22 July
2026 and for general release to licensed healthcare providers.

On 23 February 2026, the Company announced that it had secured guaranteed advance
payments of US$2.4m over the period to 31 December 2026, and a further minimum of
US$3.5m of guaranteed payments over the seven years following an extension of the
current agreement to 2031, guaranteeing payments beyond the initial seven-year period
of the licence. Minimum royalties to be paid as part of the Company’s licensing 
agreement with BIO are based on a 10% royalty on gross sales over the term of the
agreement which commenced on 18 October 2024.

BIO’s go to market strategy to secure early adoption is to target the private pay
market which includes key opinion leaders, clinical concierge services, occupational
health schemes and insurance groups. To achieve national coverage, BIO plans to 
partner with selected clinical laboratory groups, especially large, centralised 
facilities that can deliver resilience, testing at scale and have established routes
to clinical partners. The agreement between BIO and BBG, a healthcare services organisation
with expertise in laboratory medicine, biomanufacturing, blood banking and translational
science, that was announced on 3 August 2026, is a further step towards commercialisation
of the Company’s minimally invasive blood test in regions facing a significant lung
cancer burden and health disparities. BBG is one of the largest biological testing
laboratories in the United States, testing over 50 million samples annually, operating
in state-of-the-art facilities with extensive high volume automation capability 
in San Antonio, Texas.

The Company will continue to support BIO in its roll out programme, including support
for BBG to achieve validation for the Test in the near term, while also focusing
on completing its validation programme with European laboratory partners and in 
the UK with the NHS.

Because the Test is a laboratory-developed test (“LDT”), each CLIA-certified laboratory
performing the assay must complete independent validation to verify analytical performance
and meet rigorous quality standards. CLIA approval is regulated by the Centers for
Medicare & Medicaid Services and signifies that a laboratory’s testing processes
and assays meet US federal standards for clinical accuracy, reliability, and patient
safety. CLIA compliance is also mandatory for a laboratory to receive Medicare and
Medicaid reimbursements.

On 25 February 2026, the US Government announced several actions to strengthen oversight
of Medicare and Medicaid programmes. This included the launch of the CRUSH Initiative(
Comprehensive Regulations to Uncover Suspicious Healthcare) Request for Information(
RFI); a 6-month nationwide moratorium on new Medicare enrolment for certain medical
product suppliers, and deferral of US$259.5 million in federal Medicaid funds to
Minnesota pending review of questionable claims. The CRUSH initiative signals a 
more aggressive federal strategy to combat healthcare fraud through expanded oversight.
While these efforts may strengthen programme integrity, implementation is impacting
clinical laboratory supply chains, leading to reimbursement restrictions, delays
in payments and potential suspension of laboratory operations.

In this climate, the clinical laboratory market in the USA can create uncertainty
and financial pressure, especially for companies reliant on reimbursement from federal
government budgets. This may affect the ability of the Company’s partners to meet
their obligations to the Company and has resulted in disruption to operational capabilities
at BIO’s initial laboratory partner. BIO’s additional laboratory partner, BBG, is
not directly dependent on federal budget reimbursements because it operates a non-
profit and B2B revenue model through commercial partnerships, biotech contracts,
contract development and manufacturing organization services, and private licensing
agreements and the provision of advanced specialty services. If additional guaranteed
royalties and advance royalty payments were delayed or not received, the Company
may need to seek alternative funding.

BIO is initially focused on the private pay market, concierge clinical practices,
occupational health and insurance companies, which are not affected by federal budgets.
BIO is also adding large clinical laboratories which are significantly more resilient
to federal funding restrictions.

> **Commenting, Allan Syms, Executive Chairman of Cizzle Biotechnology, said:**
> _“The Company has now moved from its R&D phase to commercialisation of its proprietary
> CIZ1B biomarker test for early-stage lung cancer. The focus is now on securing
> early adoption in the USA private pay market, including among doctors, concierge
> groups, occupational health and insurance groups. We continue to work closely 
> with our licensing partner, Cizzle Bio, and its laboratory partners. We have now
> secured a new revenue-sharing model under which all advance royalties are recognised
> as upfront and milestone payments, enabling the Company to immediately earn royalties
> on all sales going forward.”_

Share on:
